Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Gynecologic 4Classical hematology 4Myeloid 3Genitourinary 3Thoracic 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Venous Thromboembolism 1Sarcoma 1Hematoma 1Bone Neoplasms 1

Interventions

Cyclophosphamide 54Specimen Handling 50Magnetic Resonance Spectroscopy 49pembrolizumab 43Doxorubicin 43Radiotherapy 42Temozolomide 37Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Surgical Procedures, Operative 19Ifosfamide 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12Etoposide 12Blood Specimen Collection 12Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Aspirin × Sarcoma × 1 year × Clear all
NCT03244020 2025-10-03

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Massachusetts General Hospital

Phase 4 Enrolling by invitation
2,868 enrolled
Classical hematologySarcoma

Bone Neoplasms, Hematoma, Sarcoma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡